UniProt Q9UF33 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: Catalytic (683-end)high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 | 0.534 |
| 2 | Crizotinib | 100.0% | 0.0% | 91.39 | 0.581 |
| 3 | Tivozanib | 98.3% | 1.7% | 92.42 | 0.673 |
| 4 | Vandetanib | 97.3% | 2.7% | 95.74 | 0.723 |
| 5 | Cabozantinib | 95.7% | 4.3% | 92.73 | 0.751 |
| 6 | Ripretinib | 94.1% | 5.9% | 92.95 | 0.674 |
| 7 | Afatinib | 93.0% | 7.0% | 98.50 | 0.709 |
| 8 | Selpercatinib | 93.0% | 7.0% | 96.72 | 0.635 |
| 9 | Bosutinib | 92.3% | 7.7% | 87.22 | 0.555 |
| 10 | Canertinib | 92.1% | 7.9% | 96.49 | 0.671 |
| 11 | Repotrectinib | 91.4% | 8.6% | 84.21 | 0.608 |
| 12 | Fostamatinib | 88.3% | 11.7% | 96.74 | 0.613 |
| 13 | Neratinib | 85.2% | 14.8% | 93.18 | 0.597 |
| 14 | Nintedanib | 83.8% | 16.2% | 90.23 | 0.608 |
| 15 | Gilteritinib | 82.8% | 17.2% | 88.97 | 0.506 |
| 16 | Dacomitinib | 79.1% | 20.9% | 97.99 | 0.664 |
| 17 | Gefitinib | 77.4% | 22.6% | 99.25 | 0.650 |
| 18 | Regorafenib | 75.5% | 24.5% | 95.99 | 0.719 |
| 19 | Dasatinib | 65.8% | 34.2% | 87.97 | 0.699 |
| 20 | Pralsetinib | 63.3% | 36.7% | 93.43 | 0.643 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.26
- Epithelial log2(TPM+1): 0.51
- Fold change: -0.25
- Status: No significant change
High-confidence drugs
- Afatinib — inh 93.0% · KISS 46.22
- Vandetanib — inh 97.3% · KISS 44.37
- Tivozanib — inh 98.3% · KISS 41.35
Selectivity landscape vs inhibition on EPHA6
Each point is one of the 92 approved drugs; color = inhibition % on EPHA6.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…